Bosh sahifaI1DX34 • BVMF
add
Idexx Laboratories Inc Bdr
Yopilish kursi
516,27 R$
Yillik diapazon
476,97 R$ - 558,30 R$
Bozor kapitalizatsiyasi
33,77 mlrd USD
Oʻrtacha hajm
1,00
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 954,29 mln | 5,84% |
Joriy xarajat | 308,97 mln | 10,01% |
Sof foyda | 216,15 mln | 11,12% |
Sof foyda marjasi | 22,65 | 5,01% |
Har bir ulushga tushum | 2,62 | 12,93% |
EBITDA | 295,39 mln | 7,40% |
Amaldagi soliq stavkasi | 15,69% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 288,27 mln | -36,50% |
Jami aktivlari | 3,29 mlrd | 1,03% |
Jami passivlari | 1,70 mlrd | -4,35% |
Umumiy kapital | 1,60 mlrd | — |
Tarqatilgan aksiyalar | 81,33 mln | — |
Narxi/balansdagi bahosi | 26,41 | — |
Aktivlardan daromad | 19,69% | — |
Kapitaldan daromad | 25,17% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 216,15 mln | 11,12% |
Operatsiyalardan naqd pul | 262,02 mln | 4,87% |
Sarmoyadan naqd pul | -39,84 mln | -30,91% |
Moliyadan naqd pul | -232,78 mln | -128,57% |
Naqd pulning sof oʻzgarishi | -20,37 mln | -116,66% |
Boʻsh pul | 170,52 mln | -25,07% |
Haqida
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
IDEXX offers products to customers in over 175 countries around the world and employs approximately 9,200 people in full-and part-time positions. There are three main segments of the company: Companion Animal Group, Water, and Livestock, Poultry and Dairy. In addition, the company also manufactures and sells pet-side SNAP tests for a variety of animal health diagnostic uses.
In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO. Wikipedia
CEO
Tashkil etilgan
19-dek, 1983
Sayt
Xodimlar soni
11 000
